DK2130023T3 - Stabiliseret hæmatoxylin - Google Patents
Stabiliseret hæmatoxylin Download PDFInfo
- Publication number
- DK2130023T3 DK2130023T3 DK08743909.7T DK08743909T DK2130023T3 DK 2130023 T3 DK2130023 T3 DK 2130023T3 DK 08743909 T DK08743909 T DK 08743909T DK 2130023 T3 DK2130023 T3 DK 2130023T3
- Authority
- DK
- Denmark
- Prior art keywords
- hematoxylin
- composition
- working agent
- cyclodextrin
- staining
- Prior art date
Links
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 title claims description 202
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 claims description 104
- 239000000203 mixture Substances 0.000 claims description 90
- 229920000858 Cyclodextrin Polymers 0.000 claims description 49
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 42
- 238000010186 staining Methods 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 35
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 34
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- 239000007800 oxidant agent Substances 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 24
- 230000001590 oxidative effect Effects 0.000 claims description 22
- 239000000126 substance Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 230000001744 histochemical effect Effects 0.000 claims description 12
- 229920005862 polyol Polymers 0.000 claims description 11
- 150000003077 polyols Chemical class 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 229910052782 aluminium Inorganic materials 0.000 claims description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 8
- 239000003125 aqueous solvent Substances 0.000 claims description 8
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 claims description 8
- 239000011697 sodium iodate Substances 0.000 claims description 8
- 235000015281 sodium iodate Nutrition 0.000 claims description 8
- 229940032753 sodium iodate Drugs 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 4
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052797 bismuth Inorganic materials 0.000 claims description 4
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052750 molybdenum Inorganic materials 0.000 claims description 4
- 239000011733 molybdenum Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 229910052720 vanadium Inorganic materials 0.000 claims description 4
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052726 zirconium Inorganic materials 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 claims description 2
- MPVDXIMFBOLMNW-ISLYRVAYSA-N 7-hydroxy-8-[(E)-phenyldiazenyl]naphthalene-1,3-disulfonic acid Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1\N=N\C1=CC=CC=C1 MPVDXIMFBOLMNW-ISLYRVAYSA-N 0.000 claims description 2
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 claims description 2
- DGOBMKYRQHEFGQ-UHFFFAOYSA-L acid green 5 Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 DGOBMKYRQHEFGQ-UHFFFAOYSA-L 0.000 claims description 2
- 230000002380 cytological effect Effects 0.000 claims description 2
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 claims description 2
- 235000019240 fast green FCF Nutrition 0.000 claims description 2
- 229940101209 mercuric oxide Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 239000012286 potassium permanganate Substances 0.000 claims description 2
- 230000001373 regressive effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 238000005554 pickling Methods 0.000 claims 2
- WLKAMFOFXYCYDK-UHFFFAOYSA-N [5-amino-4-[[3-[(2-amino-4-azaniumyl-5-methylphenyl)diazenyl]-4-methylphenyl]diazenyl]-2-methylphenyl]azanium;dichloride Chemical compound [Cl-].[Cl-].CC1=CC=C(N=NC=2C(=CC([NH3+])=C(C)C=2)N)C=C1N=NC1=CC(C)=C([NH3+])C=C1N WLKAMFOFXYCYDK-UHFFFAOYSA-N 0.000 claims 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims 1
- 239000006059 cover glass Substances 0.000 claims 1
- 229960001841 potassium permanganate Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 32
- 239000001116 FEMA 4028 Substances 0.000 description 21
- 239000003963 antioxidant agent Substances 0.000 description 21
- 235000006708 antioxidants Nutrition 0.000 description 21
- 229960004853 betadex Drugs 0.000 description 21
- 239000012472 biological sample Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000003078 antioxidant effect Effects 0.000 description 12
- 238000007254 oxidation reaction Methods 0.000 description 12
- 239000000975 dye Substances 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 11
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 7
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 6
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 6
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000007447 staining method Methods 0.000 description 6
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 5
- 239000012192 staining solution Substances 0.000 description 5
- 241001510071 Pyrrhocoridae Species 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940097362 cyclodextrins Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- BUACSMWVFUNQET-UHFFFAOYSA-H dialuminum;trisulfate;hydrate Chemical compound O.[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O BUACSMWVFUNQET-UHFFFAOYSA-H 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 3
- -1 n-octyl Chemical group 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 235000010388 propyl gallate Nutrition 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- AMVQGJHFDJVOOB-UHFFFAOYSA-H aluminium sulfate octadecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O AMVQGJHFDJVOOB-UHFFFAOYSA-H 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000012864 cross contamination Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- LBBAKTMYSIFTBS-UHFFFAOYSA-N 3-[(4-aminophenyl)diazenyl]benzene-1,2-diamine Chemical compound C1=CC(N)=CC=C1N=NC1=CC=CC(N)=C1N LBBAKTMYSIFTBS-UHFFFAOYSA-N 0.000 description 1
- WZUKKIPWIPZMAS-UHFFFAOYSA-K Ammonium alum Chemical compound [NH4+].O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O WZUKKIPWIPZMAS-UHFFFAOYSA-K 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000004214 Fast Green FCF Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000001164 aluminium sulphate Substances 0.000 description 1
- 235000011128 aluminium sulphate Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940051132 light green sf yellowish Drugs 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 229950001060 parsalmide Drugs 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Claims (13)
1. Stabiliseret hæmatoxylinsammensætning til farvning af et væv eller cytologisk prøve, omfattende: et opløsningsmiddel; hæmatoxylin; en mængde af en kemisk oxidant der er tilstrækkelig til at omdanne mindst én del af hæmatoxylinet til hæmatein; et bejdsemiddel; og både cyclodextrin og hydroquinon.
2. Sammensætningen ifølge krav 1, hvor opløsningsmidlet omfatter én eller flere af vand, en lavere alkanol, og en polyol.
3. Sammensætningen ifølge krav 2, hvor polyolen omfatter én eller flere af glycerol, ethylenglycol, propylenglycol, poly(ethylenglycol), og poly(propylenglycol).
4. Sammensætningen ifølge krav 3, hvor én eller flere af ethylenglycol og propylenglycol omfatter 10 til 30 volumenprocent af en vandig opløsningsmiddelsammensætning.
5. Sammensætningen ifølge et hvilket som helst af kravene 1 til 4, hvor den kemiske oxidant er én eller flere af natriumiodat, mercurioxid, kaliumpermanganat, kaliumperiodat, og hydrogenperoxid.
6. Sammensætningen ifølge et hvilket som helst af kravene 1 til 5, hvor bejdsemidlet omfatter én eller flere af et aluminiumbejdsemiddel, et jernbejdsemiddel, et bismuthbejdsemiddel, et kopperbejdsemiddel, et molybdænbejdsemiddel, et vanadiumbejdsemiddel, og et zirconiumbejdsemiddel, hvor aluminumbejdsemidlet er alun eller aluminiumsulfat.
7. Sammensætningen ifølge et hvilket som helst af kravene 1 til 6, yderligere omfattende en syre, hvor syren omfatter eddikesyre.
8. Sammensætningen ifølge et hvilket som helst af kravene 1 til 7, omfattende en blanding af vand og ethylenglycol som opløsningsmidlet, natriumiodat som oxidanten, og aluminumsulfat som bejdsemidlet, hvor et molforhold af hæmatoxylin til oxidant i sammensætningen er mellem 6:1 og 1:1, og hvor et molforhold af hæmatoxylin til bejdsemidlet i sammensætningen er mellem 2:1 og 1:100.
9. Fremgangsmåde til fremstilling af en stabiliseret hæmatoxylinsammensætning til histokemisk farvning af en vævs- eller cytologiprøve, omfattende: danne en hæmateinopløsning; tilsætte et bejdsemiddel til hæmateinopløsningen for at danne en farveopløsning; og tilsætte både cyclodextrin og hydroquinon til farveopløsningen for at danne den stabiliserede hæmatoxylinsammensætning, hvor dannelsen af hæmateinopløsningen omfatter opløse hæmatoxylin i et opløsningsmiddel, og tilsætte en mængde af en kemisk oxidant der er tilstrækkelig til at omdanne mindst én del af hæmatoxylinet til hæmatein.
10. Fremgangsmåden ifølge krav 9, hvor opløsningsmidlet omfatter vand og en polyol, hvor polyolen er én eller flere af glycerol, ethylenglycol, og propylenglycol, og hvor én eller flere af ethylenglycol og propylenglycol omfatter 10 til 30 volumenprocent af en vandig opløsningsmiddelsammensætning.
11. Fremgangsmåden ifølge krav 9 eller 10, hvor bejdsen omfatter én eller flere af et aluminumbejdsemiddel, et jernbejdsemiddel, et bismuthbejdsemiddel, et kobberbejdsemiddel, et molybdænbejdsemiddel, et vanadiumbejdsemiddel, og et zirconiumbejdsemiddel, hvor aluminumbejdsemidlet er alun- eller aluminiumsulfat.
12. Automatiseret fremgangsmåde til histokemisk farvning af en vævs- eller cytologiprøve, omfattende at bringe prøven i kontakt med en hæmatoxylinsammensætning som beskrevet i et hvilket som helst af kravene 1 til 8, hvor prøven er anbragt på et substrat.
13. Fremgangsmåden ifølge krav 12, yderligere omfattende at bringe prøven i kontakt med en modfarve, hvor prøven bringes i kontakt med en hæmatoxylinsammensætning der omfatter en progressiv eller regressiv hæmatoxylinfarvningsprotokol, idet substratet omfatter et mikroskop dækglas, og modfarven omfatter én eller flere af eosin Y, orange G, lys grøn SF gullig, Bismarck Brown, fast green FCF, OA-6, EA25, EA36, EA50, og EA65.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89500707P | 2007-03-15 | 2007-03-15 | |
| PCT/US2008/057035 WO2008112993A1 (en) | 2007-03-15 | 2008-03-14 | Stabilized hematoxylin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2130023T3 true DK2130023T3 (da) | 2015-06-08 |
Family
ID=39523477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08743909.7T DK2130023T3 (da) | 2007-03-15 | 2008-03-14 | Stabiliseret hæmatoxylin |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8263361B2 (da) |
| EP (1) | EP2130023B1 (da) |
| JP (1) | JP5424904B2 (da) |
| AU (1) | AU2008224935B2 (da) |
| CA (1) | CA2678903C (da) |
| DK (1) | DK2130023T3 (da) |
| ES (1) | ES2541804T3 (da) |
| WO (1) | WO2008112993A1 (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008112993A1 (en) | 2007-03-15 | 2008-09-18 | Ventana Medical Systems, Inc. | Stabilized hematoxylin |
| EP2663852A1 (en) * | 2011-01-10 | 2013-11-20 | Ventana Medical Systems, Inc. | Hematoxylin staining method |
| CN103874913B (zh) | 2011-06-17 | 2017-04-26 | 罗氏血液诊断股份有限公司 | 用于生物样品的组织加工的溶液 |
| US20130203109A1 (en) * | 2012-01-26 | 2013-08-08 | Leica Biosystems Richmond, Inc. | Methods and Compositions for Hematoxylin and Eosin Staining |
| ITCA20120004A1 (it) * | 2012-03-30 | 2012-06-29 | Abdelkrim Harchi | Unico reattivo disidratante e diafanizzante per istologia e citologia non nocivo e non tossico, biodegradabile 88%, a bassa volatilita' |
| CA2884555C (en) | 2012-10-08 | 2023-01-03 | Ventana Medical Systems, Inc. | Methods, kits, and systems for clarifying pigmented samples |
| WO2014079802A2 (en) | 2012-11-20 | 2014-05-30 | Ventana Medical Systems, Inc. | Laser ablation inductively-coupled plasma mass spectral tissue diagnostics |
| JP6232138B2 (ja) * | 2013-12-13 | 2017-11-15 | ベンタナ メディカル システムズ， インコーポレイテッド | 生物学的試料の組織学的処理のための染色試薬および他の液体ならびに関連技術 |
| JP6302066B2 (ja) | 2013-12-13 | 2018-03-28 | ベンタナ メディカル システムズ， インコーポレイテッド | 顕微鏡スライドを熱処理する自動化された処理システムおよび方法 |
| CN117054211A (zh) | 2013-12-13 | 2023-11-14 | 文塔纳医疗系统公司 | 生物样本的自动化组织学处理及相关的技术 |
| JP6378770B2 (ja) | 2013-12-13 | 2018-08-22 | ベンタナ メディカル システムズ， インコーポレイテッド | 生物学的試料の自動化された組織学的処理の文脈における熱管理および関連技術 |
| AU2015367646B2 (en) * | 2014-12-18 | 2019-11-07 | Ventana Medical Systems, Inc. | Hematoxylin solution comprising chloride and sulphate, and methods of preparation and use |
| CA2980876C (en) | 2015-04-20 | 2020-04-28 | Ventana Medical Systems, Inc. | Inkjet deposition of reagents for histological samples |
| EP3298381B1 (en) | 2015-05-22 | 2023-01-25 | Ventana Medical Systems, Inc. | METHOD AND APPARATUS FOR THE REMOVAL OR REDUCTION OF 
PRECIPITATES FORMED IN HEMATOXYLIN SOLUTIONS |
| CN104893359A (zh) * | 2015-06-02 | 2015-09-09 | 运城市妇幼保健院 | 一种脱落细胞标本快速染色剂及其制备方法 |
| WO2018073283A1 (en) | 2016-10-19 | 2018-04-26 | F. Hoffmann-La Roche Ag | Systems and methods for staining of biological samples |
| AU2018267059B2 (en) * | 2017-05-10 | 2021-08-12 | Ventana Medical Systems, Inc. | Stabilized two-part hematoxylin solution utilizing pH adjustment |
| EP4147024A2 (en) * | 2020-05-08 | 2023-03-15 | Ventana Medical Systems, Inc. | Semi-synthesis and use of racemic hematoxylin |
| IT202100018434A1 (it) * | 2021-07-13 | 2023-01-13 | Diapath S P A | Composizioni coloranti per campioni biologici, citologici, istologici e autoptici. |
| CN113790945B (zh) * | 2021-09-23 | 2024-02-20 | 南昌雨露实验器材有限公司 | 一种改良的苏木精染液及其制备方法 |
| CN114624084A (zh) * | 2022-03-18 | 2022-06-14 | 深圳市贝安特医疗技术有限公司 | 一种病理组织切片染色试剂盒的制备、染色方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0244309B2 (ja) * | 1982-09-16 | 1990-10-03 | Wako Pure Chem Ind Ltd | Anteinahematokishirinyozai |
| JPS59219270A (ja) | 1983-05-30 | 1984-12-10 | Wako Pure Chem Ind Ltd | テトラゾリウム塩を含有する溶液の安定化方法 |
| US4502864A (en) * | 1984-04-25 | 1985-03-05 | Ciba-Geigy Corporation | Crown ether complexes of direct yellow 11 and dyestuff containing same |
| US4816244A (en) | 1986-02-14 | 1989-03-28 | Sigma Chemical Company | Stabilized stain solutions containing aliphatic and aromatic alcohols |
| JP2702211B2 (ja) * | 1989-02-03 | 1998-01-21 | サクラ精機株式会社 | ヘマトキシリン染色液 |
| JPH0372414A (ja) | 1989-05-23 | 1991-03-27 | Hoyu Co Ltd | エアゾール状毛髪染色剤 |
| WO1991005605A1 (en) | 1989-10-10 | 1991-05-02 | Kosak Kenneth M | Cyclodextrin labels for immunoassay and biochemical analysis |
| US5108505A (en) | 1990-05-16 | 1992-04-28 | Hewlett-Packard Company | Waterfast inks via cyclodextrin inclusion complex |
| JP2548627B2 (ja) * | 1990-11-29 | 1996-10-30 | ホーユー株式会社 | エアゾール状毛髪染色剤 |
| JPH05130890A (ja) * | 1991-11-08 | 1993-05-28 | Bio Meito:Kk | 真菌の染色方法及びその試薬 |
| US5296472A (en) * | 1991-12-05 | 1994-03-22 | Vyrex Corporation | Methods for delipidation of skin and cerumen removal |
| US5772699A (en) * | 1995-03-13 | 1998-06-30 | Crompton & Knowles Corporation | Stable aqueous reactive dye composition and method for stabilizing an aqueous reactive dye composition |
| JP3898239B2 (ja) * | 1995-05-11 | 2007-03-28 | 大日本印刷株式会社 | バッグインボックス用包装袋 |
| CO4440539A1 (es) | 1995-06-05 | 1997-05-07 | Kmberly Clark Corp | Tinta mejorada para impresoras de chorro de tinta |
| US5679573A (en) | 1995-07-27 | 1997-10-21 | Abbott Laboratories | Stabilized aqueous steroid immunoassay standards with cyclodextrins |
| DE69620428T2 (de) | 1995-11-28 | 2002-11-14 | Kimberly Clark Co | Lichtstabilisierte fabstoffzusammensetzungen |
| EP0941293A2 (en) * | 1996-11-27 | 1999-09-15 | Kimberly-Clark Worldwide, Inc. | Improved substrates and colorant stabilizers |
| US5788754A (en) | 1997-03-03 | 1998-08-04 | Hewlett-Packard Company | Ink-jet inks for improved image quality |
| FR2783050B1 (fr) * | 1998-09-09 | 2000-12-08 | Atochem Elf Sa | Solution aqueuse a base d'un colorant azoique, son procede de fabrication et son utilisation |
| JP2000187033A (ja) | 1998-12-21 | 2000-07-04 | Wako Pure Chem Ind Ltd | 細胞染色液 |
| DE19919089A1 (de) * | 1999-04-27 | 2000-11-23 | Cognis Deutschland Gmbh | Haarfärbepräparate |
| DE19962228A1 (de) * | 1999-12-22 | 2001-06-28 | Basf Ag | Reaktivfarbstoffgemische |
| JP2003073591A (ja) | 2001-09-03 | 2003-03-12 | Fuji Photo Film Co Ltd | インク組成物およびインクジェット記録方法 |
| US6730151B2 (en) * | 2002-01-25 | 2004-05-04 | Hewlett-Packard Development Company, L.P. | Ink jet dye design |
| US7468161B2 (en) | 2002-04-15 | 2008-12-23 | Ventana Medical Systems, Inc. | Automated high volume slide processing system |
| JP4299150B2 (ja) | 2002-04-15 | 2009-07-22 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 大容量のスライドを自動染色するシステム |
| AU2003302137A1 (en) * | 2002-07-15 | 2004-06-15 | Technical Instrument San Francisco | Quality control of assays |
| CA2501132A1 (en) | 2002-10-09 | 2004-04-22 | Insert Therapeutics, Inc. | Cyclodextrin-based materials, compositions and uses related thereto |
| JP4437220B2 (ja) * | 2003-06-03 | 2010-03-24 | 独立行政法人産業技術総合研究所 | 色素包接化合物の製造方法 |
| JP2005060293A (ja) * | 2003-08-12 | 2005-03-10 | Daiko Boeki Kk | 染毛料 |
| KR100437274B1 (ko) * | 2003-10-15 | 2004-06-24 | 주식회사 케이엠에스아이 | 연골재생제로서 아피제닌을 함유하는 골관절염 치료 조성물 |
| US20060000034A1 (en) | 2004-06-30 | 2006-01-05 | Mcgrath Kevin P | Textile ink composition |
| US7760614B2 (en) * | 2005-11-21 | 2010-07-20 | General Electric Company | Optical article having an electrically responsive layer as an anti-theft feature and a system and method for inhibiting theft |
| WO2008073902A2 (en) * | 2006-12-12 | 2008-06-19 | Cytyc Corporation | Method for improving the shelf-life of hematoxylin staining solutions |
| WO2008112993A1 (en) | 2007-03-15 | 2008-09-18 | Ventana Medical Systems, Inc. | Stabilized hematoxylin |
-
2008
- 2008-03-14 WO PCT/US2008/057035 patent/WO2008112993A1/en active Application Filing
- 2008-03-14 CA CA2678903A patent/CA2678903C/en active Active
- 2008-03-14 JP JP2009553811A patent/JP5424904B2/ja active Active
- 2008-03-14 ES ES08743909.7T patent/ES2541804T3/es active Active
- 2008-03-14 EP EP20080743909 patent/EP2130023B1/en active Active
- 2008-03-14 US US12/048,749 patent/US8263361B2/en active Active
- 2008-03-14 DK DK08743909.7T patent/DK2130023T3/da active
- 2008-03-14 AU AU2008224935A patent/AU2008224935B2/en active Active
-
2012
- 2012-06-22 US US13/531,348 patent/US8551731B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5424904B2 (ja) | 2014-02-26 |
| US20120276584A1 (en) | 2012-11-01 |
| AU2008224935B2 (en) | 2013-07-25 |
| CA2678903A1 (en) | 2008-09-18 |
| WO2008112993A1 (en) | 2008-09-18 |
| AU2008224935A1 (en) | 2008-09-18 |
| CA2678903C (en) | 2016-12-20 |
| US8263361B2 (en) | 2012-09-11 |
| ES2541804T3 (es) | 2015-07-24 |
| JP2010521678A (ja) | 2010-06-24 |
| EP2130023B1 (en) | 2015-05-06 |
| US20080227143A1 (en) | 2008-09-18 |
| EP2130023A1 (en) | 2009-12-09 |
| US8551731B2 (en) | 2013-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2130023T3 (da) | Stabiliseret hæmatoxylin | |
| AU2018267059B2 (en) | Stabilized two-part hematoxylin solution utilizing pH adjustment | |
| WO2012096842A1 (en) | Hematoxylin staining method | |
| JP2020523615A (ja) | 特殊染色用のプロセス記録スライド | |
| US10830675B2 (en) | Autostainer hematoxylin and methods of use | |
| US9366604B2 (en) | Cytological or histological binding composition and staining methods | |
| KR101543306B1 (ko) | 세포 보존용액 | |
| KR101435786B1 (ko) | 세포 보존액 |